Parkinson's Progression Markers Initiative brain autopsy program. Parkinsonism & related disorders Bukhari, S. A., Nudelman, K. N., Rumbaugh, M., Richeson, P., Fox, E. J., Montine, K. S., Aldecoa, I., Garrido, A., Franz, J., Stadelmann, C., Vonsattel, J. P., Poston, K. L., Foroud, T. M., Montine, T. J. 2022; 101: 62-65


We report on the initial 17 (11 male:6 female) brain autopsies from across Europe and the United States in the Parkinson's Progression Markers Initiative (PPMI). Clinical diagnoses were Parkinson's disease (n = 15), multiple system atrophy (n = 1), and Dementia with Lewy bodies (n = 1); average age of death = 72 ± 8 yr. Cognitive assessment at last evaluation was 5 with normal cognition, 7 with mild cognitive impairment, and 5 with dementia. Genetic assessment showed 4 participants were heterozygous or homozygous for GBA N370S and 3 were heterozygous carriers for LRRK2 R1441G or G2019S; 1 was an APOE e2 carrier and 5 were APOE e4 carriers. Longitudinal DAT neuroimaging as well as CSF and plasma biomarker data are summarized. Neuropathologic examination confirmed all clinical diagnoses and showed the expected frequencies of common comorbidities; no evidence of chronic traumatic encephalopathy was observed. Thus, brain autopsy data can provide confirmation, clarification, and new insights into the PD progression observed during life. As it grows, the PPMI brain autopsy program will provide a deeply-annotated research resource to the community of investigators focused on developing biomarkers for PD progression.

View details for DOI 10.1016/j.parkreldis.2022.06.017

View details for PubMedID 35803091